ArticleDiscover biotechnology2025
Carboxymethyl kappa carrageenan polyelectrolyte multilayers as blood contacting surfaces.
Article in Discover biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antithrombotic Polymers: A Narrative Review on Current and Future Strategies for Their Design, Synthesis, and Application.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research introduces carboxymethyl kappa-carrageenan-chitosan polyelectrolyte multilayers as a promising and sustainable alternative to heparin, used in surface treatments for blood-contacting medical devices. The polysaccharide-based surface coatings have good cytocompatibility and resist microbial adhesion of both Pseudomonas aeruginosa and Staphylococcus aureus. The blood compatibility of surfaces containing carboxymethyl-kappa-carrageenan was directly compared to similar polyelectrolyte multilayers containing heparin. The carboxymethyl-kappa-carrageenan surfaces inhibit whole-blood clotting like heparin-containing surfaces. Blood clotting is mediated by both protein-surface and cell-surface interactions. The carboxymethyl-kappa-carrageenan surfaces adsorb more fibrinogen and less albumin than the heparin surfaces, and they also exhibit reduced platelet and leukocyte adhesion, compared to heparin surfaces. These results suggest that carboxymethyl-kappa-carrageenan may represent a sustainable alternative to heparin as an anticoagulant surface modification. Supplementary Information: The online version contains supplementary material available at 10.1007/s44340-025-00043-w.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.